POON CHRISTINE A

POON CHRISTINE A has engaged in a mix of buying and selling activity across four companies—PRU (Prudential Financial), REGN (Regeneron Pharmaceuticals), NBIX (Neurocrine Biosciences), and SHW (Sherwin-Williams)—with a slight net buying bias. According to SEC Form 4 filings, Poon executed 33 transactions totaling $4.89 million in buys and $4.25 million in sales. The most notable activity occurred in REGN, where a $1.41 million acquisition on October 30, 2025, was followed by a series of sales the day prior, including dispositions worth $1.78 million, $1.25 million, and $467,428. Smaller but consistent transactions in PRU, primarily labeled as derivative acquisitions (Code A), appeared in clusters, such as three purchases on March 12, 2026, totaling $26,593.92, and similar patterns in December and September 2025. Recent activity skews toward selling, with six dispositions and no buys in the latest filings. The PRU transactions, while smaller in scale, show recurring acquisitions likely tied to equity awards, whereas the REGN trades involved more substantial market sales. Poon’s involvement with NBIX and SHW was minimal, with zero-dollar acquisitions and a single $8,438.65 buy in SHW in early 2025. The data suggests a focus on REGN and PRU, with a shift toward reducing positions in late 2025 and early 2026, particularly in Regeneron. The pattern reflects a combination of equity compensation realization and discretionary sales, though the precise nature of the derivative transactions remains unclear without additional context.